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Abstract Posterior cortical atrophy (PCA) is a group of neu-
rodegenerative dementing disorders characterized by initial
predominant visual complaints followed by progressive decline
in cognitive functions. The visuospatial and visuoperceptual
defects arise from the dysfunction of, respectively, the dorsal
(occipito-parietal) and the ventral (occipito-temporal) streams.
Clinical symptoms, results of neuropsychological examination,
and findings of posterior cerebral atrophy and/or posterior
hypoperfusion/hypometabolism contribute to the diagnosis.
However, owing to the insidious onset of PCA and the non-
specificity of initial symptoms, the diagnosis is often delayed.
Specific etiologies include Alzheimer’s disease, dementia with
Lewy bodies, subcortical gliosis, corticobasal degeneration, and
prion-associated diseases. Alzheimer’s disease accounts for at
least 80 % of PCA cases. Recent research has concentrated on
better defining the clinical presentation of PCA, improving
neuroimaging analysis, testing new neuroimaging techniques,
and developing biological measurements. Selected recent pa-
pers on PCA are reviewed in this article.
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Introduction
Posterior cortical atrophy (PCA) is a group of neurodegenera-
tive disorders in which early complaints are predominantly
visual. This syndrome was first described in 1988 when
Benson et al. [1] reported five patients with prominent visual
complaints and who all exhibited both Balint’s and
Gerstmann’s syndromes. Owing to the presence of preponder-
ant posterior atrophy of the brain onmagnetic resonance imagin
(MRI), they coined the term PCA [1]. Subsequent pathological
studies have revealed Alzheimer’s disease (AD) to be the most
frequent cause of PCA, accounting for 80% of cases [2–4]. AD
can present in patients older than 65 years (late-onset AD) or in
younger patients (early-onset AD). Most frequently, AD man-
ifests in patients older than 65 years with a prominent amnestic
syndrome. On the contrary, patients with early-onset AD do not
present prominent amnestic syndrome until late in their disease,
but exhibit different prominent symptoms, such as limb aprax-
ia, disturbances of either language or executive functions, or
visuospatial functions (PCA) [5].While the term “visual variant
of AD” has been used popularly in the past, the more generic
term PCA is presently favored because of both the heteroge-
neous etiologies that may present in such fashion and the fact
that pathology confirmation is often lacking. As PCA results
most frequently from AD pathology, the vast majority of recent
literature on PCA is comparing PCA of presumed AD pathol-
ogy to typical amnestic AD.
Since 1988, PCA has been gradually more frequently recog-
nized and better characterized. PCA affects patients of both
sexes, usually in their 50s or early 60s. The onset is insidious,
and patients with PCA frequently report symptoms that started
years before diagnosis. Incidence and prevalence of PCA are
unknown, but PCA accounts for 4% of dementia patients and is
estimated to represent 5 % of all AD presentations [6]. Initial
complaints are mostly related to vision, reading, driving, and
walking. Most of these symptoms can be suggestive of distur-
bances affecting either the afferent visual retino-calcarine or the
efferent oculomotor pathways. In fact, the visual symptoms of
PCA result from an impairment at a higher level of visual
processing (beyond the occipital cortical V1, or Brodmann’s
area 17) and both the dorsal stream (occipito-parietal cortex,
“where” pathway) and the ventral stream (occipito-temporal,
“what” pathway) can be involved to various degrees [7, 8•].
Symptoms in PCA are then related to an impairment of the
This article is part of the Topical Collection on Neuro-Ophthalmology
F.<X. Borruat (*)
Department of Ophthalmology, University of Lausanne, Jules Gonin
Eye Hospital, Neuro-Ophthalmology Unit, Avenue de France 15,
1004 Lausanne, Switzerland
e-mail: francois.borruat@fa2.ch
Curr Neurol Neurosci Rep (2013) 13:406
DOI 10.1007/s11910-013-0406-8
The large majority of PCA articles relate to its most fre-
quent etiology: Alzheimer’s pathology. At an early stage,
PCA patients differ from typical AD for the followings: mem-
ory disturbances are prominent in typical AD, but absent or
minimal in PCA; visual symptoms predominate in PCA;
patient insight in PCA is usually preserved until late in the
disease. Owing to the relative preservation of personal insight,
some patients with PCA develop frank anxiety or depression,
which can contribute to a delayed diagnosis. However, PCA is
a progressive disorder and, over a few years, patients ultimate-
ly develop a more global dementia. Even if AD is the under-
lying pathology in more than 80 % of cases, PCA remains a
heterogenous group of diseases. Hence, despite the growing
interest of researchers for PCA, research efforts are still ham-
pered by the lack of definite clinical and paraclinical criteria
for PCA. In 2012, the first meeting of the International
Working Party on PCA was held in Vancouver, Canada,
prior to the Alzheimer’s Association International Con-
ference, with a primary goal to define standardized clinical
criteria for PCA [9]. Standardized diagnostic criteria and more
homogenous and comparable cohorts of PCA patients might
ultimately lead to the possibility of testing specific therapies
for PCA.
Clinical Manifestations of PCA
Patients with PCA present with prominent visual symptoms,
including difficulties in reading a text; problems with driving
or parking a car; difficulties in identifying objects; walking
difficulties in the presence of uneven ground, stairs, sidewalk
borders, or escalators; and light sensitivity, sustained after-
images, or even visual hallucinations. Despite prominent vi-
sual symptoms, results from ophthalmological examinations
are frequently unremarkable (or, at least, do not explain fully
the clinical picture). Therefore, some patients will benefit
from unnecessary procedures, such as cataract surgery.
Owing to the posterior localization of cerebral involvement
in PCA, retrochiasmal visual pathways dysfunction can occur
in PCA. Indeed, some cases of homonymous visual field
defects were reported in the early literature on PCA, but both
their prevalence and incidence was thought to be low. Recent
reports tend to demonstrate that the incidence of homonymous
defects in PCA is higher than previously thought, ranging
from 50 % to 100 % [10–13]. However, owing to the
dementing nature of PCA, visual field examination can some-
times be challenging, and neither computerized static nor
kinetic manual perimetry can be performed adequately by
some patients.
Andrade et al. [14] reported visual hemineglect to be a
frequent finding in PCA patients (16/24 patients). According
to these authors, the line bisection test was more sensitive for
detecting visual hemineglect in PCA compared to target can-
cellation tasks, and the presence of visual hemineglect did not
correlate with disease duration or severity [14]. In another
paper, the same group [15] reported a series of 15 PCA patients
in whom visual left hemineglect (5/7 cases) was more frequent
and more severe than right hemineglect (2/7 cases).
Neuroimaging results revealed the left hemineglect to be asso-
ciated with the presence of both atrophy and hypoperfusion of
the parieto-temporal and prefrontal regions [15]. In a later
paper, Andrade et al. [16•] further explored visual hemineglect
in PCA, correlating visuospatial deficits and altered cerebral
perfusion in a series of 27 patients. Visual hemineglect was
found in 16 patients, with a surprisingly high incidence of right
visual hemineglect (7/16 patients). They explained this high
rate of right visual hemineglect by the presence of concurrent
lesions of the right hemisphere [16•].
Basic visual processing and higher-order visual functions
were assessed by Lehmann et al. [17•] in 21 PCA patients and
correlated to cortical thickness. The basic visual skills were
assessed with six tests: form detection, form coherence, form
discrimination, color discrimination, motion coherence, and
point localization. At least one result of basic visual function
was impaired in all PCA patients, whereas 81 % exhibited
abnormal results for at least 3/6 tests. Thus, no case of “pure”
visual agnosia was found amongst 21 PCA patients. Patients
with visuospatial defects (dorsal stream dysfunction) tended to
exhibit lower occipito-parietal cortical thickness, whereas
there was a trend towards lower occipito-temporal cortical
thickness in patients with visuoperceptual defects (ventral
stream dysfunction). However, despite these trends, neuroim-
aging per se did not support differentiation of PCA into dorsal
versus ventral subtypes owing to the overlap of magnetic
resonance imaging (MRI) findings between the two clinical
groups [17•]. Amongst a group of 39 PCA patients, working
memory deficits, simultanagnosia, and limb apraxia were
found to be the most common abnormalities, occurring in
100 %, 92 %, and 95 %, respectively, of the patients. A full
Balint’s or Gerstmann’s syndrome was encountered in 31 %
and 36 %, respectively, of the patients [18•]. The combination
of these two syndromes, as originally reported by Benson,
must be very rare.
Optic ataxia is part of Balint’s syndrome, a common disor-
der found in PCA. In optic ataxia from causes other than PCA,
grasping performances were improved with eye closure.
Quantitative measurements of visuomotor deficits were
performed in four PCA patients [19•]. Contrary to patients
with optic ataxia from another cause, none of the PCA patients
improved in reaching and grasping abilities with eye closure.
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visuospatial and/or visuoperceptual performances. Neuro-
psychologic examination can disclose any of the following:
alexia, Balint’s syndrome (oculomotor apraxia, simultanagnosia,
optic ataxia), Gerstmann’s syndrome (agraphia, acalculia, finger
anomia, right-left disorientation), prosopagnosia, or environ-
mental agnosia.
Average speed was decreased upon eye closure, and, under
visual guidance, all PCA patients produced highly curved
reach trajectories when reaching either at midline or at the
periphery. Both slowing the reaching movements and increas-
ing the curvature of the reach trajectories might represent a
compensation strategy developed as the consequence of de-
creased central parietal motor control [19•].
Reading difficulties are a frequent complaint in PCA, re-
ported by about 80 % of patients. Yong et al. [20] tested the
reading performances of two PCA patients with prominent
visual complaints. Despite a widespread dysfunction at the
lower levels of visual processing (both patients failed all 10
tasks assessing early visual, visuoperceptual, and visuospatial
processing) their reading performances were normal or near
normal. The visual word form system is in the left fusiform
gyrus, which was found to be intact in both patients. Some
patients with PCA can retain normal reading despite wide-
spread visual dysfunction [20].
Patients with PCA can complain of unusual symptoms,
which can be puzzling to the physician. Crutch et al. [21]
reported an interesting patient who complained of four symp-
toms, two of them previously reported in PCA (prolonged
chromatic afterimages and reverse size effects) and two not
previously reported in PCA (perceivedmotion of static stimuli
and room tilt illusion). Reverse size effects (the ability to
better read small than large prints) result from reduction in
the “effective visual field” (i.e., attention disorder and eye
movement disorders). Prolonged chromatic afterimages are
thought to result from an excessive rebound inhibition of
previously excited color selective neurons in V1 (primary
visual cortex, occipital cortical area 17), as inhibitory inter-
neurons in V1 are relatively spared in AD. Perceived motion
of static stimuli was attributed to abnormal eye movements,
namely unstable fixation. Room tilt illusion may result from
lesions affecting the multimodal cells in the posterior parietal
lobe, as they play an important role in integrating inputs from
the visual, vestibular, and proprioceptive systems [21].
Picture agnosia is a specific lack of recognition of objects
on pictures, whereas the real objects are either better or nor-
mally identified. While viewing a real object, binocular dis-
parity cues can help its identification, whereas identification
of an object from a two-dimensional photography requires
preserved stereoscopic visual memory. Picture agnosia was
found in 2/3 patients with PCA, but not in a group of seven
typical amnestic AD patients serving as controls. The differ-
ence in the distribution of AD pathology between PCA and
typical amnestic AD probably accounted for the absence of
picture agnosia in typical amnestic AD patients. For some
PCA patients, two-dimensional objects can be more difficult
to identify than their three-dimensional counterparts [22].
Gardini et al. [23] reported a patient at an advanced stage of
PCA. Neuropsychological examination disclosed two previous-
ly unreported deficits: defective visuospatial mental imagery and
defective autobiographical memory. Anatomical and functional
investigations with MRI and single-photon emission computer-
ized tomography (SPECT) showed the former symptoms to be
related to hypoperfusion in the parahippocampus and precuneus,
whilst the later was associated with reduced blood flow in the
parahippocampi [23].
Language impairment was initially reported by Benson
et al. [1] in their seminal paper on PCA. However, until
recently, very few reports have addressed language impair-
ment in PCA. Magnin et al. [24] described a “logopenic
syndrome” in 8/9 PCA patients, characterized by anomia,
fluency impairment, and length-dependent deficit. The left
parieto-temporal junction seems to play an important role in
the “logopenic syndrome” of PCA patients [24]. Crutch et al.
[25] examined the language profile both in PCA patients and
in patients with the logopenic/phonological aphasia form of
AD. Results were abnormal in both groups but PCA patients
performed better than the logopenic/phonological aphasia pa-
tients. Detailed linguistic assessment might help to differenti-
ate PCA due to AD from other causes of PCA [25].
Olfaction was found to be impaired similarly in patients
with PCA and with typical amnestic AD. Further, around
30 % of both PCA and AD patients exhibited a complete loss
of olfaction. The high frequency of abnormal olfactory test
results contrasted with the fact that olfactory symptoms were
rarely reported by patients. The abnormal odor identification
was associated with dysfunction of the right anteromedial
temporal lobe dysfunction [26].
Neuroimaging of PCA
Since 1988, anatomical neuroimaging (mainly MRI) has been
used to help diagnose PCA [1]. Occipitoparietal atrophy with-
out mesiotemporal atrophy is classically described as the
initial MRI findings of PCA. However, some cases exhibit
either minimal or general cortical atrophy. When MRI does
not support a diagnosis of PCA, but the patient’s symptoms
suggest PCA, functional neuroimaging can help the clinician
to establish the diagnosis. In PCA, functional neuroimaging
usually discloses selective posterior hypometabolism by
fluorodeoxyglucose positron emission tomography (FDG-
PET) or hypoperfusion by SPECT. However, with the diag-
nosis of PCA being usually delayed, the first neuroimaging is
performed at an already moderately advanced stage of PCA.
MRI Studies
The natural history of PCA on MRI was provided by
Kennedy et al. [27•]. They reported one patient who
volunteered as a healthy control, but complained of memory
loss. Initial neuropsychological examination was normal, as
was his MRI. Subsequently, over 5 years, both repeat MRI
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and clinical examinations revealed anomalies that progressively
worsened over time. Cortical atrophy affected first the superior
parietal and inferior temporal cortices. One year later, the
inferior parietal and occipital areas were involved. Another year
later, the medial temporal lobe was affected, and ultimately
global posterior cerebral atrophy was present [27•].
At the early stage of the disease, MRI can separate PCA
from typical AD: the former will show predominant posterior
cortical atrophy, whereas the latter will show prominent atrophy
of themedial temporal cortex.With an increased duration of the
disease, it may become difficult to distinguish PCA from
typical AD on MRI. Lehmann et al. [28•] reported serial
imaging in 17 PCA patients, 16 typical AD patients, and 18
healthy controls. After 5 years of symptom duration, the MRI
appearances of PCA and AD were alike: a widespread atrophy
of grey matter. The rate of brain atrophy was five times higher
in both PCA and typical AD when compared with healthy
normals [28•]. Whereas MRI can differentiate PCA
(occipitoparietal atrophy) from typical amnestic AD (mesio-
temporal atrophy) at the early stage of the disease, it will not be
able to do so at an advanced stage of neurodegeneration, the
degree of grey matter atrophy being similar in AD and PCA.
Assessment of cortical atrophy on MRI can be done either
via complex techniques such as volumetric analysis or via a
visual subjective method, which is quicker. Koedam et al. [29]
developed an MRI subjective visual rating scale for cortical
atrophy (posterior, medial temporal lobe, and global atrophy),
which they applied to a group of 60 AD patients, comparing
their results to 40 normal controls and 20 patients with other
dementias. Intra-rater agreement was excellent, and the inter-
rater agreement was good althoughmore variable, as expected
with a subjectivemethod. Inter-rater agreement was best when
assessing medial temporal lobe atrophy and was good, but
lower, for posterior atrophy assessment. The visual rating
method proposed by Koedam et al. [29] may be useful in a
clinical setting for separating AD from other dementias.
Lehmann et al. [30•] concluded that posterior cerebral atrophy
on MRI was a neuroimaging marker of AD, even in the
absence of medial temporal lobe atrophy. The finding of
posterior cerebral atrophy on MRI may then help to distin-
guish AD from other dementias [30•]. However, the specific-
ity of posterior atrophy on MRI for AD was challenged by
O’Donovan et al. [31]. In a series of older patients, they found
that posterior atrophy on MRI was not a reliable marker in
older patients to distinguish AD from controls or to distin-
guish AD from dementia with Lewy bodies [31]. Cortical
thickness was measured in 54 patients with PCA (n=25),
typical amnestic AD (n=14), and also logopenic-progressive
aphasia (n=15), another distinctive presentation of AD.
Temporo-parietal cortical thinning was common to all three
forms of AD. Specific areas of atrophy in PCAwere bilateral
occipital and parietal regions. For the logopenic form of AD,
the left temporo-parietal and superior temporal lobes were
specifically thinned, whereas results for typical amnestic AD
were distributed along a continuum between the previous two
extremes [32•].
PCA is a neurodegenerative disorder, the diagnosis of
which is suspected by clinical presentation and supported by
results of neuropsychological tests and neuroimaging. The
rare incidence of PCA precludes large prospective studies to
be easily performed. Alves et al. [33] published the first meta-
analysis of studies on brain morphometry in PCA. They
collated 205 PCA patients (vs 184 typical AD and 249 healthy
controls) from 11 published studies. The results of their anal-
ysis confirmed the previously published results: brain atrophy
in PCA predominates in the right occipital gyrus and the right
posterior lobe, whereas atrophy in typical AD predominates in
the left hippocampus and parahippocampal gyrus [33].
Recent articles have hypothesized that cognitive functions
might not depend solely on grey matter dysfunction, but could
depend on the integrity of brain networks. Cognitive dysfunc-
tion might then result from interruption of information flow
between different cortical areas. Using tractography,Migliaccio
et al. [34] reported the findings of prominent white matter
damage in the right hemisphere in addition to typical gray
matter atrophy in one patient with PCA. This single case report
supports the hypothesis of neural network dysfunction (white
matter lesions) in neurodegenerative disorders. White matter
atrophy of the ventral and dorsal streams have also been dem-
onstrated by diffusion-tensor MRI in a series of seven PCA
patients [35•]. Of note, all seven patients presented mostly
symptoms derived from dysfunction of the ventral stream,
whereas only 2/7 exhibited symptoms derived also from dys-
function of the dorsal stream. All seven patients exhibited
abnormalities in the ventral and fronto-occipital visual path-
ways (i.e., inferior longitudinal and inferior fronto-occipital
fasciculi), whereas signal abnormalities in the dorsal visual
pathways (fronto-parietal superior longitudinal fasciculus) were
found only in the two patients with symptoms of visuospatial
dysfunction. The results of this study suggest that Gerstmann’s
syndrome results from intraparietal white matter disconnection,
another argument for the neural network dysfunction hypothe-
sis [35•]. White matter atrophy can contribute to the clinical
presentation of patients with PCA or other variants of AD
versus typical AD. White matter atrophy in PCA was more
pronounced in the occipital lobe, whereas typical AD patients
showed more damage in the medial temporal regions [36•].
SPECT Studies
Kas et al. [18•] studied a group of 39 PCA patients and
correlated their cognitive deficits with the results of functional
neuroimaging by SPECT [18•]. A group of 24 typical AD
patients and 24 age-matched healthy controls was also studied.
Posterior hypoperfusion was found in all PCA patients, and the
extent of the hypoperfused areas progressively increased over
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time. Initially, hypoperfusion was found in the dorsal parietal
cortices, with later involvement of the occipito-temporal corti-
ces. When compared with typical AD patients, PCAwas char-
acterized by a more severe posterior hypoperfusion (occipital,
parietal and posterior temporal cortices). Analysis of PCA
patients by subgroups (symptom duration ≤ 2 years, ≤ 3 years,
and > 3 years) failed to reveal any specific hypoperfusion
patterns [18•]. Further, they demonstrated also hypoperfusion
of a small temporal area corresponding to the frontal eye field
(FEF), as reported previously byNestor et al. [37]. Involvement
of FEF could play a role in the oculomotor apraxia present in
some PCA patients [18•, 37]. Another SPECT study in a series
of 27 PCA patients revealed that visuospatial deficits, namely
hemineglect, were associated with contralateral parietal cortex
hypoperfusion and interhemispheric perfusion asymmetries
[16•].
PET Studies
In PCA, selective posterior hypometabolism can be demon-
strated by FDG-PET, and FDG-PET has been used for several
years to support a clinical suspicion of PCA. The pathology in
the vast majority of patients with PCA (80 %) is AD, and
cerebral amyloid deposits play a major role in AD. In vivo
imaging of cerebral amyloid deposits is now available with
two different PET techniques: Pittsburgh compound B-PET
(PiB-PET) and (18)F-florbetapir-PET. Investigation of PCA
with these recent techniques has just begun and reports are
few. Rosenbloom et al. [38•] reported the results of both PiB-
PET and FDG-PET in 12 PCA patients, 14 typical AD pa-
tients, and 30 normal controls. PiB-PET revealed diffuse
deposits of amyloid in both PCA and typical AD patients,
whereas glucose metabolism, as measured with FDG-PET,
was found to be significantly decreased in the inferior
occipitotemporal cortex of PCA patients. PiB-PET does not
allow separation of PCA and AD, at least in the mild-to-
moderate stage of the disease. The authors concluded that
both clinical features and hypometabolism of PCA were not
related to fibrillary amyloid distribution. Individual suscepti-
bility and vulnerability of specific cortical networks might
determine the type of neurodegenerative pattern, that is, the
specific presentation of AD [38•]. Similar results were report-
ed by Cruz de Sousa et al. [39] in a series of nine PCA and
nine matched AD patients. The authors found that PiB-PET
abnormalities were similar between typical AD and PCA [39].
PiB-PET might not be helpful in differentiating typical AD
from PCA.
PET using (18)F-florbetapir has not been applied yet to
specifically study PCA. However, one study in AD patients
revealed regional variations in the amount of amyloid de-
posits. Namely, prominent deposits of amyloid were found
in the posterior association areas, and maximal deposition was
in the frontal cortex [40].
Whereas FDG-PET remains a very helpful neuroimaging
technique in the diagnosis of PCA, the implications of the
newest techniques, PiB-PET and (18)F-florbetapir-PET, are
not yet well defined.
Pathology of PCA
Etiologies of PCA include AD, dementia with Lewy bodies,
subcortical gliosis, corticobasal degeneration, and prion-
associated diseases. AD is the most frequent cause of PCA,
accounting for about 80 % of cases [2–4]. Recent pathology
reports on PCA are scarce. Depaz et al. [41] reported on the
occurrence of an early and longstanding dementia in five
members of a family. Clinical and radiological presentations
were typical of PCA. However, prion disease was suspected
when one patient developed a subacute myoclonic encepha-
lopathy with specific electroencephalography abnormalities,
16 years after disease onset. A mutation of the prion protein
gene consisting of five octa repeats motifs located between R2
and R3 was found in the proband, as well as in other family
members. Mutations in the prion gene protein can induce a
dementing disorder resembling AD or PCA [41].
Several neurodegenerative diseases result from an abnor-
mal accumulation of tau protein fragments within the central
nervous system. Three- and four-repeat tauopathies have been
associated with various clinical diagnoses. Jellinger et al. [42]
reported a case of a patient with a post-mortem diagnosis of
four-repeat tauopathy who clinically presented PCAwith dys-
function of both ventral and dorsal streams [42]. CSF was
atypical for AD (elevated t-tau, but normal p-tau protein, and
elevated β-amyloid 1–42; see the “Biology Studies” section).
Post-mortem, a diagnosis of possible corticobasal degenera-
tion was proposed in the total absence of cerebral amyloid
deposits and due to the presence of tau-pathology [42].
One patient diagnosed early in childhood with Tourette’s
syndrome developed PCA in his 60s. The association might
have been fortuitous, but it is notable that Tourette’s syn-
drome has been reported to occur with other form of demen-
tias [43].
Genetics of PCA
The genetics of PCA are still elusive.Mutations in presenilin 1
gene (PSEN1) are commonly found in familial early-onset
AD, and result in a reduction of γ-synthetase activity—an
enzyme involved in amyloid metabolism. One patient with
PCAwas recently reported to harbor a novel genetic mutation,
at codon 211 of the PSEN1 gene. Results from an in silico
(computer-based) analysis of the mutation lead the authors to
conclude that the novel PSEN1 I211M mutation could be
responsible for the PCA phenotype [44].
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Biology Studies: CSF and Serum Abnormalities in PCA
There is a major interest in being able to diagnose PCA in vivo
with some certainty. The CSF biomarkers of typical AD have
been defined as a combination of elevated total-tau (t-tau) and
phosphorylated-tau (p-tau) proteins, and decreased amyloid-β
42 (Aβ42). When these three biomarkers are abnormal, AD
neuropathology is predicted with both a high sensitivity
(90 %) and specificity (85 %). Seguin et al. [45•] assessed
the cerebrospinal fluid (CSF) biomarkers in a series of 22
patients with PCA, and 77 % of cases (17/22) showed CSF
profiles identical to typical AD. Three patients showed CSF
profiles that were atypical for AD (either elevated t-tau and p-
tau, or decreased Aβ42). Only 2/22 patients exhibited a nor-
mal CSF profile, and these patients belonged to a subgroup of
three clinically defined PCA-corticobasal syndrome patients.
CSF can be useful to determine in vivo which etiology is
underlying PCA [45•]. Similar results were obtained from
Cruz de Sousa et al. [46] who reported the same CSF profile
in nine patients with PCA and nine matched typical AD
patients. Both PCA and typical AD patients exhibited elevated
t-tau and p-tau proteins levels, and decreased Aβ42 level.
Cruz de Sousa et al. [47] refined further the analyses of CSF
biomarkers. The t-tau/Aβ42 and p-tau/Aβ42 ratios allowed to
differentiate with both high sensitivity and specificity typical
AD patients from other causes of cortical dementias, namely
semantic and frontotemporal dementias. However, these bio-
markers were not useful in differentiating typical AD from its
variants, PCA and logopenic AD [47]. Beaufils et al. [48]
refined the analysis of CSF by introducing the ratio of Aβ42/
Aβ40, which was decreased in all PCA (n=22) and typical
AD (n=22) patients of their series. In the presence of an
atypical CSF profile for AD, the use of the Aβ42/Aβ40 ratio
proved useful in establishing the diagnosis of AD pathology,
as demonstrated in 4/22 PCA patients who exhibited an
otherwise atypical CSF profile (t-tau and/or p-tau not
elevated) [48].
Anti-amyloid-β antibodies are found in the serum of nor-
mal elderly individuals, and their role in the pathogenesis of
AD is not clear. In one study of 13 typical AD and eight PCA
patients, Dorothée et al. [49•] reported a specific decrease in
the level of anti-amyloid-β antibodies in the serum of the PCA
patients only. Further, the serum level of IgG1 was signifi-
cantly more lowered than for IgG3. As IgG1 and IgG3 are
both involved in neuroprotection and neuroinflammation, this
specific serologic pattern might have significance in the path-
ogenesis of PCA [49•].
Treatment of PCA
Unfortunately, very little has been published on therapeutic
options in PCA. Patients with PCA are usually treated with
cholinesterase inhibitors, by analogy with treatment of typical
AD. However, there is no evidence-based medicine for the
efficacy of cholinesterase inhibitors in PCA. A review on the
pharmacologic therapies of typical AD emphasized that, since
2003, no new drug was marketed for AD. Today, cholinester-
ase inhibitors and memantine are the only options for typical
AD. Future therapies might be directed at controlling the
levels of amyloid deposits, decreasing tau aggregates, or mod-
ulating neurotransmitters [50•]. McMonagle [51] reported his
experience in treating 10 PCA patients with donepezil in an
unblinded and pragmatic study. Global cognitive scores were
significantly improved, but no improvement was detectable
for the visuospatial scores.
Non-pharmacologic therapies have been proposed for a
few PCA patients. A psycho-educative program was offered
to four PCA patients and their caregivers [52]. A team
consisting of a neurologist, psychologist, nurse, and
ergotherapist animated the sessions. Both patients and care-
givers benefited from this approach by improving their overall
knowledge of PCA. Further, the anxiety of the caregivers
decreased significantly. However the quality of life of the
PCA patients did not improve [52]. A multidisciplinary
Table 1 Diagnosis of posterior cortical atrophy
Core features
- Insidious onset and gradual progression
- Prominent and disabling visual complaints
○ No ocular disease explaining the symptoms
○ Visuoperceptual and visuospatial impairment
- Relatively preserved anterograde memory and insight
- Any of the following:
○ Balint’s syndrome (partial or complete)
○ Gerstmann’s syndrome (partial or complete)
○ Homonymous visual field defect
○ Environmental disorientation
Supportive features
- Alexia
- Prosopagnosia
- Prolonged chromatic after-images
- Dressing or ideomotor apraxia
- Presenile onset
Investigations
- Neuropsychological assessment
- Structural neuroimaging (magnetic resonance imaging/
computed tomography)
○ Absence of tumor or stroke
○ Evidence of posterior atrophy (occipital, parietal and
temporal areas)
- Functional neuroimaging (positron emission tomography/
single-photon emission computerizd tomography)
○ Posterior hypometabolism/hypoperfusion
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approach combining speech therapy, occupational therapy,
and physiotherapy was applied to a single PCA patient.
Marked improvement of the patient’s autonomy was observed
after 6 months of therapy, thanks to a better understanding of
PCA and to the development of compensation strategies for
daily life activities (e.g., dressing, reading) [53].
Conclusions
PCA is a progressive neurodegenerative heterogeneous disor-
der with a poor prognosis, as an evolution towards global
dementia is frequent. PCA is suspected when complex unex-
plained visual symptoms are prominent in a patient usually in
her/his 50s. Diagnosis will be supported by formal neuropsy-
chological examination and neuroimaging (Table 1). The ma-
jority of PCA cases results from AD pathology, and results
from recent neuroimaging and biological studies in PCA con-
firm that association in vivo. Significant improvement in clin-
ical diagnosis, neuroimaging and biological studies have re-
cently occurred and help to distinguish PCA from other
dementing conditions. Unfortunately, there is still no specific
treatment for PCA, and this is owing to both the rarity and the
heterogeneity of the disorder. However, the specific interests of
research teams for PCA and the recent launch of the
International Working Party on PCA [8•] will certainly contrib-
ute to improve both our knowledge of PCA and the manage-
ment of PCA patients in a near future.
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